Cantor Fitzgerald assumed coverage on shares of Protara Therapeutics (NASDAQ:TARA – Free Report) in a research note released on Friday morning, MarketBeat reports. The firm issued an overweight rating on the stock.
Several other brokerages have also issued reports on TARA. Guggenheim reiterated a “buy” rating and issued a $20.00 price target on shares of Protara Therapeutics in a research note on Friday, December 6th. HC Wainwright restated a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a report on Thursday, March 6th. Finally, Lifesci Capital initiated coverage on Protara Therapeutics in a report on Tuesday, March 11th. They set an “outperform” rating and a $22.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $22.50.
Read Our Latest Report on Protara Therapeutics
Protara Therapeutics Stock Performance
Protara Therapeutics (NASDAQ:TARA – Get Free Report) last issued its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.09. On average, research analysts predict that Protara Therapeutics will post -3.32 earnings per share for the current fiscal year.
Institutional Trading of Protara Therapeutics
A number of large investors have recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. raised its holdings in shares of Protara Therapeutics by 40.8% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 179,125 shares of the company’s stock valued at $328,000 after purchasing an additional 51,944 shares during the period. XTX Topco Ltd acquired a new position in Protara Therapeutics during the third quarter worth approximately $60,000. Geode Capital Management LLC increased its position in Protara Therapeutics by 21.0% during the third quarter. Geode Capital Management LLC now owns 170,040 shares of the company’s stock worth $311,000 after buying an additional 29,514 shares during the last quarter. Bailard Inc. bought a new stake in Protara Therapeutics in the fourth quarter valued at approximately $157,000. Finally, Commonwealth Equity Services LLC lifted its position in shares of Protara Therapeutics by 90.4% in the fourth quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company’s stock valued at $195,000 after buying an additional 17,572 shares during the last quarter. Institutional investors and hedge funds own 38.13% of the company’s stock.
Protara Therapeutics Company Profile
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Featured Stories
- Five stocks we like better than Protara Therapeutics
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- How to Build the Ultimate Everything ETF Portfolio
- Trading Stocks: RSI and Why it’s Useful
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.